DANA-FARBER CANCER INSTITUTE
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1947-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.dana-farber.org/
Pleurectomy/Decortication Followed by Intrathoracic/Intraperitoneal Heated Cisplatin for Malignant Pleural Mesothelioma
- Conditions
- Pleural MesotheliomaMalignant Pleural Mesothelioma
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2014-03-27
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 70
- Registration Number
- NCT00165555
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
Counseling Interventions for BRCA 1/2 Cancer Susceptibility Testing
- Conditions
- Breast CancerOvarian Cancer
- Interventions
- Procedure: Genetic CounselingProcedure: Informed Consent Counseling
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2012-08-09
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 150
- Registration Number
- NCT00165152
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
A Trial of Thalidomide, Celecoxib, Etoposide and Cyclophosphamide in Patients With Relapsed or Progressive Cancer
- Conditions
- Neoplasms
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2011-07-07
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 20
- Registration Number
- NCT00165451
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors
- Conditions
- Neuroendocrine Tumor
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2009-04-28
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 32
- Registration Number
- NCT00165230
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconness Medical Center, Boston, Massachusetts, United States
Doxorubicin, Cisplatin, 5-Fluorouracil in Patients With Advanced Adenocarcinoma of the Stomach or Esophagus
- Conditions
- Adenocarcinoma of StomachAdenocarcinoma of GE JunctionAdenocarcinoma of Esophagus
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2009-04-28
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 32
- Registration Number
- NCT00165191
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric Cancer
- Conditions
- Esophageal CancerGastric CancerGE Junction Cancer
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2009-04-28
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 54
- Registration Number
- NCT00165464
- Locations
- 🇺🇸
Faulkner Hospital, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
MRI-guided Bone Marrow Biopsies of Prostate Cancer Patients
- Conditions
- Prostate Cancer
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2009-12-09
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 20
- Registration Number
- NCT00165386
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Dosimetric Analysis of Vaginal Cuff Brachytherapy in Endometrial Carcinoma
- Conditions
- Endometrial CarcinomaCervix CancerCarcinoma of the Uterus
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2009-11-01
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 40
- Registration Number
- NCT00165126
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Prolonged Daily Temozolomide for Low-Grade Glioma
- Conditions
- GliomaAstrocytomaOligodendroglioma
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2009-11-01
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 46
- Registration Number
- NCT00165360
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Neuroblastoma and Sarcomas
- Conditions
- NeuroblastomaEwings SarcomaNon-rhabdomyosarcoma Soft Tissue Sarcoma
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2009-11-01
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 20
- Registration Number
- NCT00165139
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States